Biomolecular drug delivery engineers create innovative systems that transport delicate biomolecules—such as proteins, peptides, and nucleic acids—to targeted tissues or cells efficiently and safely. These biomolecules often face significant challenges, including instability, enzymatic degradation, and poor cellular uptake, which can hinder their therapeutic effectiveness. To overcome these obstacles, these engineers design and optimize delivery platforms like nanoparticles, liposomes, and polymeric carriers that protect the biomolecules, control their release, and enhance targeting capabilities. Their work is vital in advancing treatments for complex diseases such as cancer, genetic disorders, and autoimmune conditions, where precision and efficacy are critical.
Biomolecular drug delivery engineers perform extensive evaluations to ensure biocompatibility, optimize pharmacokinetics, and minimize side effects. They collaborate closely with molecular biologists, pharmacologists, and clinicians to translate laboratory discoveries into effective clinical therapies. As personalized medicine and biotechnology continue to grow, these engineers play a pivotal role in tailoring therapies to individual patient needs and overcoming biological barriers. Their ongoing innovations are essential to expanding the therapeutic potential of biomolecules and improving patient outcomes. Through integrating engineering principles with biological insights, they develop solutions that are both scientifically advanced and clinically practical. Ultimately, biomolecular drug delivery engineers help bridge the gap between scientific research and practical medicine, driving forward the future of precision therapeutics.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico